NASDAQ:ITRM

Iterum Therapeutics (ITRM) Stock Price, News & Analysis

Iterum Therapeutics logo
$0.03 0.00 (0.00%)
As of 11/6/2026

About Iterum Therapeutics Stock (NASDAQ:ITRM)

Advanced

Key Stats

Today's Range
$0.03
▼
$0.03
50-Day Range
$0.03
▼
$0.03
52-Week Range
$0.03
▼
$1.42
Volume
N/A
Average Volume
4.85 million shs
Market Capitalization
$1.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Reduce

Company Overview

Iterum Therapeutics plc is a pharmaceutical company focused on developing and commercializing antibiotics for bacterial infections, including infections caused by drug-resistant pathogens. The company is headquartered in Ireland and has focused its commercial efforts on the U.S. market.

Its lead product is sulopenem, a penem-class antibiotic developed in oral and intravenous formulations. The oral formulation, marketed as Orlynvah, combines sulopenem etzadroxil with probenecid.

In October 2024, the U.S. Food and Drug Administration approved Orlynvah for certain uncomplicated urinary tract infections in adult women who have limited or no alternative oral antibacterial treatment options. The approval marked a key step in Iterum’s efforts to bring its antibiotic to patients.

AI Generated. May Contain Errors.

Receive ITRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iterum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ITRM Stock News Headlines

Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
Iterum Therapeutics Provides Business Update
Iterum Therapeutics PLC
See More Headlines

ITRM Stock Analysis - Frequently Asked Questions

Iterum Therapeutics' stock was trading at $0.3350 at the beginning of 2026. Since then, ITRM shares have decreased by 91.0% and is now trading at $0.03.

Iterum Therapeutics PLC (NASDAQ:ITRM) posted its quarterly earnings data on Friday, November, 14th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.07. The company earned $390 thousand during the quarter.
Read the conference call transcript
.

Iterum Therapeutics's stock reverse split on the morning of Thursday, August 18th 2022.The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Iterum Therapeutics (ITRM) raised $92 million in an initial public offering (IPO) on Friday, May 25th 2018. The company issued 6,150,000 shares at $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Iterum Therapeutics investors own include Atossa Genetics (ATOS), SNDL (SNDL), Tonix Pharmaceuticals (TNXP), NVIDIA (NVDA), NIO (NIO), 9 Meters Biopharma (NMTR) and Ideanomics (IDEX).

Company Calendar

Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ITRM
CIK
1659323
Fax
N/A
Employees
10
Year Founded
2015

Profitability

EPS (Trailing Twelve Months)
($0.75)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$24.77 million
Net Margins
N/A
Pretax Margin
-6,842.31%
Return on Equity
N/A
Return on Assets
-65.54%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.13
Quick Ratio
1.96

Sales & Book Value

Annual Sales
$390 thousand
Price / Sales
4.10
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.15) per share
Price / Book
-0.20

Miscellaneous

Outstanding Shares
53,292,000
Free Float
52,226,000
Market Cap
$1.60 million
Optionable
Not Optionable
Beta
2.96

Social Links

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NASDAQ:ITRM) was last updated on 11/6/2026 by MarketBeat.com Staff.
From Our Partners